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Calcium signalingCD38 catalyzes the synthesis of two structurally distinct messengers for Ca2+-mobilization, cyclic ADP-ribose
(cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP), from cytosolic substrates, NAD and
NADP, respectively. CD38 is generally thought of as a type II membrane protein with its catalytic site facing out-
side.We recently showed that CD38 exists, instead, in two oppositemembrane orientations. The determinant for
themembrane topology is unknown. Here, speciﬁc antibodies against type III CD38were designed and produced.
We show thatmutating the positively charged residues in theN-terminal tail of CD38 converted its orientation to
type III, with the catalytic domain facing the cytosol and it was fully active in producing intracellular cADPR.
Changing the serine residues to aspartate, which is functionally equivalent to phosphorylation, had a similar ef-
fect. The mutated CD38 was expressed intracellularly and was un-glycosylated. The membrane topology could
also be modulated by changing the highly conserved di-cysteine. The results indicate that the net charge of the
N-terminal segment is important in determining the membrane topology of CD38 and that the type III orienta-
tion can be a functional form of CD38 for Ca2+-signaling. This article is part of a Special Issue entitled: 13th
European Symposium on Calcium.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Release of Ca2+ from intracellular stores is a ubiquitous signaling
mechanism important in regulating a wide range of cellular functions.
The endoplasmic reticulum is the major Ca2+ store that is mobilized
by the messenger molecules inositol trisphosphate [1] and cyclic ADP-
ribose (cADPR) [2,3]. Endo-lysosomal Ca2+ stores, on the other hand,
are mobilized by another structurally different messenger, nicotinic
acid adenine dinucleotide phosphate (NAADP) [4,5]. Both cADPR
and NAADP are, however, synthesized by a multi-functional enzyme,
CD38, using NAD and NADP, respectively as substrates [6,7]. The
multi-catalytic mechanism of CD38 has beenwell elucidated by crystal-
lography and site-directedmutational analyses ([8–10] and reviewed in
[11,12]).
CD38 is a membrane protein consisting of a catalytic carboxyl
(C) domain, a single stretch of trans-membrane segment and a short
amino (N) tail of 21 residues [13]. It has long been thought to have aopean Symposium on Calcium.
logy and Biotechnology, Peking
), leehoncheung@gmail.comtype II membrane orientation with the catalytic C-domain facing outside
[13]. It has never been fully understood how an ecto-enzyme can gain
access to its intracellular substrates, NAD and NADP, and produce
the signaling messengers, cADPR and NAADP that target intracellular
Ca2+ stores. A vesicular mechanism has been proposed, positing that
CD38 can be endocytosed together with transport proteins into endo-
lysosomes. These proteins, such as connexin 43 and nucleoside trans-
porters, can thenmediate the inﬂux of substrates and efﬂux ofmessenger
products from the endo-lysosomes ([14–16] and reviewed in [17,18]).
Recently, we have shown that CD38, in fact, exists naturally in
two opposite membrane orientations in human primary monocytes
and the monocytic U937 cells, not only in the expected type II orienta-
tion but also in the opposite type III orientation, with the catalytic
C-domain facing the cytosol [19]. The type III CD38 is fully active in
producing intracellular cADPR. In this study, we further investigate
the residues in the CD38 sequence that are important in determining
the membrane topology of the expressed protein.
2. Materials and methods
2.1. Cell culture and transfection
HEK-293T cells were cultured in Dulbecco's modiﬁed Eagle's medi-
um (Invitrogen) supplemented with 10% fetal calf serum, penicillin
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atmosphere at 37 °C. LipofectAMINE™ 2000 (Invitrogen) was used to
transfect HEK-293T cells.
2.2. Constructs
To make the construct proGFPN1-CD38, the cDNA of human CD38
was subcloned from pEGFP-N1-CD38 [20] with Kpn I and Hind III. The
mutants, m1, m3–m12, m21, m11ss and m12ss were made on the
basis of proGFPN1-CD38 (wt)with the QuikChange Site-DirectedMuta-
genesis kit (Stratagene). The sequence of the mutants is shown in
Figs. 3, 5 and 7. The construction of pEGFP-sCD38 was described previ-
ously [20], fromwhich the mutant pEGFP-sCD38(N219D) was made by
mutating the fourth glycosylation sites, N219D. To make constructs
pCHMWS-CD38-EGFP, CD38-Flag and m1CD38, the corresponding
gene segments were ampliﬁed with speciﬁc primers and inserted into
pCHMWS-eGFP, a lentiviral vector [21] gifted by HKU-Pasteur Research
Centre.
2.3. Antibodies
The polyclonal antibody against the fourth glycosylation site of
human CD38 (G4S) was raised against the peptide GSRSKIFDKNSTFGS
and puriﬁed with the peptide DKNSTFG. The polyclonal antibody,
Ab77, was raised against the human C-domain of CD38 [19,20]. The
monoclonal antibody HB-7 was prepared as Ref. [19].
2.4. Fluorescence microscopy
HEK-293T cells were transfected with different constructs in
FluoroDish with cover glass bottom (World Precision Instuments,
Inc.). At 48 h post-transfection, the ﬂuorescence signals of roGFP were
acquired by a Zeiss LSM700 confocal laser scanning. For the immuno-
staining experiment, HEK-293T cells, co-transfected with m1CD38, or
wtCD38 and ER-RFP, were stained with G4S (1 μg/ml, coupled with
Alexa Fluor® 488 anti-rabbit), HB-7 (1:1000, coupled with Alexa
Fluor® 647 anti-mouse) and DAPI, a dye for nuclei. Images were ac-
quired by a Zeiss LSM510 confocal laser scanning. The ﬂuorescence pro-
ﬁle wasmeasured by the ImageJ software. A distribution index (DI)was
deﬁned as DI = ((C− B)/(E1− B) + (C− B)/(E2− B))/2, where C is
the value of the ﬂuorescence in the cytoplasm, B is background, and E1
and E2 are the values around two cell edges.
2.5. Western blot
To extract membrane proteins, cells were homogenized with
Dounce homoginizer in HB buffer (250 mM sucrose, 1 mM EDTA,
10 mM Tris–HCl buffer, pH 7.2 0.5 mM PMSF and Complete Protease
inhibitor cocktail from Roche) and centrifuged at 500 ×g for 10 min
at 4 °C to remove intact cells, nuclei and cell debris, and the membrane
fractions were prepared by centrifuging the supernatant at 100,000 ×g
for 1 h at 4 °C. Whole cells or membrane fractions were lysed with
lysis buffer (PBS, 0.5% Triton X-100, plus protease inhibitors). The
same samples were applied to two identical SDS-PAGEs and blotted
with Ab77 (1:2000) and G4S (0.5 μg/ml), respectively. The speciﬁc sig-
nal was ampliﬁed by HRP-conjugated anti-rabbit antibody, developed
by ECL substrate (Grafﬁnbio) and visualized with a Bio-rad Gel Doc XR
System. The band intensity was analyzed by the software Image Lab
(Bio-rad).
2.6. Measurements of ADP-ribosyl cyclase activity
Tomeasure ADP-ribosyl cyclase activity in vitro, HEK-293T stable cell
lines expressing CD38-EGFP (Fig. 1) or CD38-Flag (Suppl. Fig. 1) and
m1CD38 were ﬁrst constructed by using lentivector pCHMWS and
selecting single colonies expressing wildtype or mutant CD38,respectively. To remove the soluble proteins, cell pellets were resus-
pended in 10mMTris (pH 7.5)with protease inhibitors, frozen–thawed
once and the pellets after centrifugation (12,000 ×g, 4 °C, 10 min) were
resuspended in lysis buffer (PBS, 0.5% Triton X-100, protease inhibitors).
The extracts were applied to NGD assay [22] and blottedwith Ab77. The
relative cyclase activities were normalized with the corresponding
CD38 expression levels.
2.7. Measurements of intracellular cADPR contents
The cADPR-contents were measured by the cycling assay described
previously [23]. The results were presented as pmol cADPR/mg protein
or pmol cADPR/unit recombinant protein. The unit of recombinant pro-
tein was calculated by the band intensity measured in Western blots of
the cell extracts using the CD38 antibody, Ab77.
2.8. Statistical analysis
Data shown in each ﬁgure are mean ± SE from at least three
experiments.
3. Results
3.1. Development of antibodies (G4S) speciﬁc for the type III CD38
We have previously shown that CD38 not only exists in both type II
and type III orientations, but can also co-express in the same cells [19]. It
is thus necessary to develop antibodies speciﬁc for type III CD38 to facil-
itate its identiﬁcation and tracking. The strategy is to focus on the glyco-
sylation of the protein. Type II CD38 is known to be fully glycosylated at
four separate sites in the C-domain. On the other hand, type III CD38
with its C-domain facing the cytosol, is not glycosylated [19], as is sim-
ilar to most cytosolic proteins.
A polyclonal antibody was raised against a peptide of 15 residues
(GSRSKIFDKNSTFGS) covering the fourth glycosylation site (NST) of
CD38 and afﬁnity puriﬁed using a shorter peptide (DKNSTFG). The anti-
bodies (G4S) should recognize the site in type III CD38 since it is
unglycosylated, but should fail to do so if the epitope is blocked by gly-
cosylation in the type II CD38.
To test the speciﬁcity, HEK-293T cells were transfected with either
the C-domain of wildtype CD38 (sCD38) or with the glycosylation
sites mutated to aspartates (sCD38(N219D)). Both were tagged with
EGFP at the N-termini (EGFP-sCD38 and EGFP-sCD38(N219D)) for
easy visualization. We have previously demonstrated that both con-
structs are expressed in the cytosol and are without glycosylation [20].
As shown in Fig. 1A, G4S recognized the wildtype non-glycosylated
CD38 (EGFP-sCD38) very well, but not EGFP-sCD38(N219D) with the
glycosylation sites mutated. Ab77, a polyclonal antibody raised against
the C-domain of CD38 [19,20], on the other hand, recognized both.
To demonstrate that G4S can recognize full-length type III CD38,
cells were transfected with the m1CD38-roGFP construct that has the
four positive residues in the N-terminal tail of wtCD38 mutated to as-
partates and tagged with roGFP at the C-terminus. We have previously
shown that the membrane orientation of full length wildtype CD38
(wtCD38) can be converted from type II to type III by such mutations
(m1) [19]. As a negative control, cells were transfected with wtCD38-
roGFP. The Western blot shows that G4S recognized only the smaller
size m1CD38-roGFP (non-glycosylated), even though the amount of
the protein loaded onto the blot was very much lower than wtCD38-
roGFP, as detectable by Ab77 (Fig. 1B).
The m1CD38 with its catalytic C-domain facing the cytosol is fully
active enzymatically. Extracts were prepared fromHEK293T cells stably
expressing m1CD38 and the ADP-ribosyl cyclase (cyclase) activity was
measured using the NGD-assay [24]. As shown in Fig. 1C, the cyclase
activity, when normalized to the CD38 proteins expressed (Western
in Fig. 1C), of m1CD38 was essentially the same as the wildtype
Fig. 1.Development of speciﬁc antibody G4S against type III CD38.HEK-293T cells were transfected with either the C-domain of wildtype CD38 , or with its fourth glycosylation site mutated
and tagged with EGFP at the N-terminus (A. EGFP-sCD38 and EGFP-sCD38(N219D)), wildtype CD38 taggedwith roGFP at the C-terminus (B.wtCD38-roGFP), or wildtype CD38 with the
four positive residues in the N-terminal tail mutated to aspartate and tagged with roGFP at the C-terminus (B.m1CD38-roGFP). Cell extracts (A) or membrane fractions prepared by ul-
tracentrifugation (B) were probedwith either Ab77, polyclonal antibodies raised against the C-domain of wildtype CD38with its four glycosylation sitesmutated, or with G4S, polyclonal
antibodies raised against a peptide covering the fourth glycosylation site of wtCD38. C. The ADP-ribosyl cyclase (cyclase) activities weremeasured in extracts prepared fromHEK293T cells
stably expressing m1CD38 orwildtype CD38 (CD38-EGFP) using the NGD assay described in theMethods section. The relative activity was normalized to the amounts of CD38 expressed
as determined by the Western blot shown and probed with Ab77.
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Suppl. Fig. 1.
The selectivity and speciﬁcity of G4S allows its use to visualize the
sub-cellular distribution of the type III CD38. Fig. 2A shows that G4S
stained m1CD38 expressing cells and the staining was intracellular,
co-localizing with a marker for endoplasmic reticulum (ER-RFP) co-
transfected into the same cell. The sub-cellular distribution was alsoFig. 2. Subcellular distribution of m1 CD38 and wildtype CD38. A. The distribution was visualized
the type III CD38, or HB7 (purple ﬂuorescence), a monoclonal antibody against the C-domain o
B. Sub-cellular distributionwas quantiﬁed bymeasuring theﬂuorescence proﬁles of a line acros
rescence intensity ratio of the cell center to the cell edges. DI values shown were average ± SEsimilar to the staining by a monoclonal antibody against CD38 (HB7)
[20]. G4S did not recognize cells expressing wildtype CD38 (wtCD38),
which were readily detected by HB7 (lower panel, Fig. 2A). Contrary
to m1CD38, wtCD38 expressed mainly at the cell surface and the distri-
butionwas distinct from ER-RFP. The subcellular distributionwas quan-
tiﬁed by measuring the line proﬁle of ﬂuorescence intensity across the
cell. The intensity ratio of the cell edges to cell center provides aby immunoﬂuorescence using either G4S (green ﬂuorescence), an antibody selective for
f CD38. The cells were also co-transfected with an ER-marker (ER-RFP, red ﬂuorescence).
s the cell using themicrographs and calculating the distribution indexes (DI) from theﬂuo-
of 9–12 cells.
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ing cells, as compared to theDI=0.04±0.02 forwtCD38 (n=15). The
index value close to zero indicates surface expression, while a value
close to unity indicates cytosolic expression. Values higher than unity,
on the other hand, signify expression in intracellular organelles.
To conﬁrm the sub-cellular localization of m1CD38, cells were
transfected with various forms of CD38 tagged with EGFP. As shown
in Suppl. Fig. 2, consistently, the DI value of the cytosolic EGFP-sCD38
(Suppl. Fig. 2) was measured to be 0.96 ± 0.05 (n= 10), indicating cy-
tosol expression. The distribution index of m1CD38-roGFP, was mea-
sured to be 2.16 ± 0.45 (n = 15), consistent with its co-localization
with the endoplasmic reticulum that is well inside the cell and away
from the plasma membrane [19].
These results indicate that G4S can distinguish between type II and
type III CD38 and can speciﬁcally recognize the latter.3.2. Mutation of the positively charged residues of the N-terminal tail of
CD38
The “positive-inside rule” posits that the charged residues ﬂanking
the hydrophobic core of the trans-membrane segment determine the
membrane orientation of the protein, with the side having the most
net positive charges being generally cytosolic [25]. Indeed, mutation of
the four positive residues in the N-terminal tail of CD38 converts it
from type II to type III orientation [19], indicating the rule is applicable
to CD38.
To determine which of the four residues are important in determin-
ing themembrane topology of CD38, a series of constructs listed in Fig. 3
were made and expressed in HEK-293T cells. Probing the Western blot
with Ab77 revealed twomain bands. The highermolecularweight band
was the fully glycosylated type II wtCD38 (cf. wt in Fig. 3), while the
lower band was the un-glycosylated type III CD38 (cf. m1 in Fig. 3).
Cells transfected with wtCD38 expressed only type II CD38, while the
m1-transfected cells expressed mainly type III CD38. Mutation of three
positively charged residues (m21) was sufﬁcient to ensure essentially
all expressed CD38was in the type III orientation. Mutation of two pos-
itively charged residues (m11) produced both type II and type IIIFig. 3.Mutation of the positive residues in the N-terminal tail of CD38.A.HEK-293T cells were tran
or G4S. The band corresponding to glycosylated type II or the non-glycosylated type III CD38 is i
form) or type III (non-glycosylated form) CD38were quantiﬁed respectively from the Ab77 or G
error bars correspond to standard error (n = 3).proteins. Mutation of only one positive residue (m3–m6) could already
produce amounts of type III CD38 detectable by Ab77.
These results were further conﬁrmed using G4S to probe the blot.
G4S, being speciﬁc for type III CD38, revealed also that even a single
change of the positive residues to aspartate was sufﬁcient to produce
substantial amounts of type III CD38. The relative intensity of type III
CD38 produced with various mutations was quantiﬁed and compared
in Fig. 3B, with the non-glycosylated form from the G4S blots and the
glycosylated form from the Ab77 blots. Even with a single mutation,
the amounts of type III CD38 expressed were about 20–30% of that
expressed by the m1-mutation.
Subcellular distribution of various mutant proteins, as shown by the
ﬂuorescence microscopy of the roGFP tag, showed mainly surface ex-
pression for the single residue mutations (m3–m6) (Fig. 4A). Cells ex-
pressing constructs with more positive residues mutated (m11, m21
andm1) showmore intracellular expression, in consistencewith the in-
creasing amount of type III CD38 in Western blot (Fig. 3).
Cells expressing any of the mutated constructs all showed high ele-
vation of intracellular cADPR contents (Fig. 4B), indicating all themutat-
ed CD38s were enzymatically active and that the type III CD38 is fully
compatible with its signaling function. In fact, when the measured
cADPR contents were normalized to CD38 expressed, the trend strongly
indicates type III CD38s (m11, m21 and m1) were much more efﬁcient
than type II CD38 (wt) in producing cADPR inside the cells. More
conﬁrming results are shown in the Supplement section (Suppl.
Figs. 4-1 and 4-2).
3.3. Mutation of the serine residues of the N-terminal tail of CD38
That the net charge of theN-terminal tail of CD38 is critical for deter-
mining its topology raises the question of whether the charges can be
physiologically modulated. A clear possibility is phosphorylation of ser-
ine that can add two negative charges to the sequence for each residue
phosphorylated. There are three serine residues in the tail sequence
with one located next to the di-arginine connecting the trans-
membrane segment and, as shown above, ismost effective in promoting
the type III orientation. The two negative charges of the phosphate
added by phosphorylation of the serine should effectively neutralizesfectedwith various constructs listed and theWestern blotswere probedwith either Ab77
ndicated bywhite or black dots. B. The bands corresponding to either type II (glycosylated
4S blots, and plotted by normalizing to the band ofwildtype orm1 CD38, respectively. The
Fig. 4. Subcellular distribution and enzymatic activity of CD38withmutations on the positive residues.A. The distributionswere visualized byﬂuorescence of roGFP. The abbreviationswt,m3–m6,
m11,m21 andm1 are as listed in Fig. 3A.B. Intracellular cADPRwasmeasured as described in the Experimental Procedures and normalized to either total amounts of protein (upper panel) or
the combined amounts of both types of CD38 expressed and quantiﬁed as in the Ab77-blot shown in Fig. 3B. The error bars correspond to standard error (n = 3).
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endogenous phosphorylation of serine is to mutate it to aspartate,
which is shown to lead to constitutive activation of many proteins and
enzymes, producing cellular effects akin to physiological activation.
Mutation of the serine next to the di-arginine (m9) indeed produced
type III CD38 readily detectable byG4S (Fig. 5).More prominentwas the
expression with two (m10) and all three serine residues mutatedFig. 5.Mutation of the serines in the N-terminal tail of CD38. HEK-293T cells were transfectedwith
band corresponding to glycosylated type II or the non-glycosylated type III CD38 is indicated by
band of the highest intensity (B). The error bars correspond to standard error (n = 3).(m12). Type II CD38 expression detected by Ab77 (Fig. 5A), however,
remained dominant as compared with type III CD38. Additional experi-
ments showing similar results are shown in the Supplement section
(Suppl. Fig. 5).
Similar to them1-mutation of the positive residues described above,
the type III CD38 induced by the serine mutations showed intracellular
localization that ismore obviously seen in the case of them12-mutationvarious constructs listed and theWestern blots were probedwith either Ab77 or G4S. The
black orwhite dots, respectively (A) andwas quantiﬁed and plotted by normalizing to the
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m10 and m12, had elevated cADPR content, even though the type II
CD38 in the cells detected by Ab77 was expressed in lower amounts.
The clear trend is that, when normalized to the CD38 protein expressed,
themore type III CD38 expressed thehigher the efﬁciency of cADPRpro-
duction (e.g. m10 andm12, in Fig. 6B). Additional experiments showing
similar results are shown in the Supplement section (Suppl. Figs. 6-1
and 6-2).
It has recently been shown that a certain kinase is associated with
the ribosomes and can phosphorylate the nascent peptide during trans-
lation [26–28]. As is described in more detail in the Discussion section,
the resultant charge change of the nascent peptide can lead to alternate
exit from the signal recognition particle, resulting in production of type
III membrane protein [25].
3.4. Mutation of the di-cysteine of the N-terminal tail of CD38
A notable feature of the sequence of the tail of CD38 that is highly
conserved among human, chimpanzee, bovine and wolf, is the di-
cysteine located close to the trans-membrane segment. As cysteines
are amenable to modiﬁcation, such as oxidation or palmitoylation, it is
of interest to determine if its mutation affects the topology of CD38.
This is the case as shown in Fig. 7. We show above that mutating
three positive residues in the tail resulted in the expressed protein hav-
ing essentially all in type III orientation (m21). Further mutation of the
di-cysteine of m21 to di-serine (m21ss) greatly enhanced the expres-
sion of type II CD38 as detected by Ab77 (indicated by the black dot in
Fig. 7A). The amounts of type III CD38 expressed remained about the
same as detected both by Ab77 and G4S (open dot). A similar effect is
seen in the m11ss-mutation with the type II CD38 greatly increased as
compared to m11. This trend is clearly shown in Fig. 7B plotting the
quantiﬁcation of the band density. For the m21ss-mutation, the type IIFig. 6. Subcellular distribution and enzymatic activity of CD38withmutations on the serines.A. The
m10 andm12 are as listed in Fig. 3. B. Intracellular cADPR was measured as described in the Ex
the combined amounts of both types of CD38 expressed (lower panel) and quantiﬁed as in theto type III ratio was more than ﬁve folds as compared with m21, while
a two-fold increase was seen with the m11ss-mutation (Fig. 7B).
These results document that type II and type III CD38 can be individually
modulated by speciﬁc residues of the N-terminal tail. Subcellular distri-
bution analysis showed that cysteine-mutation increases the plasma
membrane localization (Fig. 7C) comparing to that of m11 and m21
(Fig. 4A).
The enhanced expression of type II CD38 in these two cases (m11ss
andm21ss), however, did not increase intracellular cADPR contents fur-
ther when normalized to the expressed CD38 (Fig. 7D), suggesting that
the type II CD38 may not be very efﬁcient in cADPR production.
4. Discussion
NAADP and cADPR were discovered more than two decades ago in
sea urchin eggs [2,3,5] and have since been established as second mes-
senger molecules regulating diverse cellular functions from plant to
human (reviewed in [11,12]). Although the catalytic mechanism of
their synthesis by CD38 is well elucidated by crystallography andmuta-
genesis ([8–10] and reviewed in [11,12]), the regulation of its enzymatic
activity remains to be worked out. The main unresolved issue centers
around the membrane topology of CD38.
We have proposed that CD38 can be expressed in both type II and
type III orientations [11,12]. Although it is not a general occurrence,
many proteins do exist in two opposite orientations. These include
prion [29], multidrug-resistance transporter [30], diacylglycerol acyl-
transferase [31], microsomal epoxide hydrolase [32], melanocortin-2
receptor accessory protein [33] and lactose permease [34], just
to name a few examples. In the case of CD38, a crucial test for the phys-
iological relevance of the type III orientation is whether the catalytic do-
main can function normallywhen exposed to the reducing environment
of the cytosol. This is of particular concern since the catalytic domaindistributionswere visualized byﬂuorescencemicroscopy of roGFP. The abbreviations;m7–
perimental Procedures and normalized to either total amounts of protein (upper panel) or
Ab77-blot shown in Fig. 5B. The error bars correspond to standard error (n = 3).
Fig. 7.Mutation of the cysteines in the N-terminal tail of CD38. A.Western blots were either probed with Ab77 or G4S. The sequences of mutants are as listed. B. The bands corresponding to
either type II or type III CD38were quantiﬁed from theAb77 orG4S blots, andplotted as the ratio of the intensity (glycosylated formversus non-glycosylated form). The error bars correspond
to standard error (n = 4). C. Fluorescence microscopy of roGFP tagged to the mutants. The DIs were calculated as in Fig. 2. D. Intracellular cADPR was measured as described in the Exper-
imental Procedures and normalized to the combined amounts of both types of CD38 expressed and quantiﬁed from the Ab77-blot. The error bars correspond to standard error (n = 3).
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activities [35,36]. The issue was resolved by directly expressing the cat-
alytic domain of CD38 in the cytosol and it was shown to be fully active
in producing intracellular cADPR [20].
Furthermore, we and others have demonstrated that type III CD38
not only is naturally present in human primarymonocytes [19] and var-
ious cell lines [19,37–39], but also its expression increases following cell
activation by stimuli, such as retinoic acid and interferon γ [19]. It is,
therefore, important to fully characterize the critical determinants of
the membrane topology of CD38.
In this study, we make selected mutations in the N-terminal tail of
CD38 and express them in HEK293 cells to assess the effect on its mem-
brane topology. We chose the HEK293 cell line as a model because the
cells do not express the ryanodine receptor and do not show any Ca2+
changes in response to cADPR [40], avoiding the potential complication
of cADPR production by the expressed CD38 constructs altering the cell
physiology.We ﬁrst conﬁrm our previous results indicatingmutation of
the four positive residues can direct the expression of CD38more or less
exclusively in the type III orientation [19]. Systematic analyses here fur-
ther show that the di-arginine next to the trans-membrane segment is
themost important and changing even a single positive residue is sufﬁ-
cient to direct the expression of signiﬁcant amounts of type III CD38.
Mutation of the three serine residues to aspartate has a similar effect
in directing the expression of type III CD38, and again with the serine
adjacent to the di-arginine being themost effective. The serinemutation
is of particular interest since it is generally regarded as the functional
equivalent of phosphorylation of the residue. It is possible that during
protein translation [26], endogenous phosphorylation of the serine res-
idues of the nascent N-terminal tail can affect the expression of the ma-
ture CD38 to the type III orientation. Indeed, there is evidence that the
N-terminal region of CD38 might be phosphorylated in a microglial
cell line upon stimulation by abscisic acid [41].
Protein synthesis generally begins in the cytosolic ribosomes. Pro-
teins destined to be secreted or sorted to other cell organelles carry an
N-terminal signal sequence that interacts with a signal recognition par-
ticle (SRP), leading to the docking of the SRP complex (ribosome, mRNAand the nascent polypeptide) to the ER membrane. Protein translation
continues, with the resultant strand passing through the polypeptide
translocator directly into the ER (reviewed in [25]). The translocation
complex has a hydrophilic channel that the nascent peptide can tread
through and a lid. If the nascentN-terminal sequence carries strong pos-
itive charges, the electrostatic repulsion with the translocation complex
bends the sequence and opens the lid of the complex. The result is a type
II protein, with the C-terminus extended to the lumen of the ER, which
is topologically equivalent to the outside of the cell.
If the nascent peptide is neutral or has low net charges, the lid will
not open and the nascent peptide treads through a side channel instead.
The rest of the C-domain is then extended into the cytosol, resulting in
the type III orientation [25].
The N-terminal tail of CD38 has a net positive charge and should
generally open the lid of the translocator and be produced as a type II
protein. It has recently been shown that an atypical kinase, mTORC2,
is associated with ribosomes and can promote co-translational phos-
phorylation of the nascent polypeptide [26]. The same kinase has
also been shown to phosphorylate an mRNA-binding protein co-
translationally [28]. Phosphorylation by protein kinase C of the nascent
polypeptide of cytochromes P450 at a threonine residue close to the
N-terminus has also been observed [27]. Phosphorylation could lead
to charge change of the nascent polypeptide and its alternate exit
through the side channel of the translocator, resulting in a type III ori-
entation of CD38. Thus, the membrane topology of CD38 may not be
ﬁxed, but could be regulated, such as by phosphorylation. Therefore,
CD38 may not necessarily be always expressed as a type II protein.
Under an appropriate condition, it can be expressed as type III as
well, as we have observed in human mononuclear cells in the blood
and in monocytic cells lines [19].
If the type III CD38 is to be physiologically relevant, it must be ﬁrmly
established that it is fully active in producing cADPR. We have done so
using the m1-mutation [19,20] and have extensively conﬁrmed it here
using various other mutated constructs. We have also determined that
the catalytic properties of the m1-CD38 are unaltered, possessing both
the cyclase and the NADase activities similar to that of the wild type
2102 Y.J. Zhao et al. / Biochimica et Biophysica Acta 1853 (2015) 2095–2103CD38 (Fig. 1C and data not shown). The general trend observed is that
the intracellular cADPR content is positively correlatedwith the expres-
sion of type III CD38.
It is of interest to note that, in the case of the cysteine-mutation, the
enhanced expression of the type II CD38 does not result in higher cADPR
content (Fig. 7), suggesting that it may not be as efﬁcient as type III
CD38. This may well be related to the vesicular nature of the signaling
mechanism of type II CD38 noted in the Introduction. The type II topol-
ogy necessitates the participation of transporters to mediate the move-
ment of substrates and products across endo-lysosomes, potentially a
less efﬁcient process than the direct catalysis of type III CD38.
The type II and type III signaling pathways are not mutually exclu-
sive but can operate side by side in cells. The type III mechanism, with
the catalytic domain in the cytosol, is amenable to many known types
of regulation, such as phosphorylation. It can be involved in fast cellular
responses, such as stimulation byhormonal agonists. On the other hand,
the type II mechanism, requiring substrate and product transport, may
be more suitable for slower and long-term responses, such as cellular
differentiation, which has been shown to be regulated by both cADPR
[42] and NAADP [43].
Results in this study show that, consistent with the “positive-inside
rule,” the charges in the N-terminal tail are critically important in deter-
mining the type III orientation of CD38. It has been proposed that the
dominance of the rule is due to the normal presence of phosphatidyl-
ethanolamine in the membrane, dampening the translocation potential
of negative residues in nascent peptide that work in opposition to the
positive-inside rule [44]. Indeed, it has been recently shown that the
two opposite orientations of lactose permease can be interconverted
by post-assembly synthesis or dilution of phosphotidyl-ethenolamine
in vivo [34]. Membrane topology, once thought of unchangeable and
solely deﬁned by the sequence, may well be altered or regulated even
after translation. It is possible that changes in the metabolic state of
cells following stimulation can lead to alternation in lipid contents and
thus the topology of signaling proteins, such as CD38, an intriguing pos-
sibility well worth exploring.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.10.028.
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